GlassScriptPhysician profile
Nancy E Pitruzzello
NPI 1265758189
$4,561.83
in general payments reported to CMS, 2019-2025
26 companies · $719 in 2025
The $719 reported for 2025 was more than what 80% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $843 · 2022: $749 · 2023: $1,318 · 2024: $932 · 2025: $719.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,949 · Education: $21.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,948.67 |
| Education | $21.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $555.91 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $370.19 | 2023-2025 | Ingrezza |
| Medtronic, INC. | $368.72 | 2022-2024 | Venaseal, Compia Mri Quad Crt-D Surescan |
| Astrazeneca Pharmaceuticals LP | $341.91 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $247.36 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $245.18 | 2024-2025 | Uptravi, Opsumit |
| Eisai INC. | $240.68 | 2024 | |
| Esperion Therapeutics, INC. | $232.48 | 2021 | |
| Genentech USA, INC. | $231.65 | 2021 | |
| Amgen INC. | $124.01 | 2023 | Lumakras |
| Alexion Pharmaceuticals, INC. | $124.01 | 2022 | |
| Xeris Pharmaceuticals, INC. | $122.40 | 2023 | Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $122.40 | 2023 | |
| Gilead Sciences, INC. | $115.17 | 2023 | Trodelvy |
| Relievant Medsystems, INC. | $114.65 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $112.17 | 2023 | Veozah |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $105.36 | 2025 | |
| Lilly USA, LLC | $98.31 | 2024 | |
| Allergan, INC. | $98.04 | 2021 | |
| Dova Pharmaceuticals | $95.00 | 2021 | |
| Neurelis, INC. | $93.52 | 2024 | Valtoco |
| Takeda Pharmaceuticals U.S.A., INC. | $89.19 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.52 | 2023 | Jardiance |
| Janssen Pharmaceuticals, INC | $79.43 | 2022 | |
| Kite Pharma, INC. | $78.42 | 2023 | |
| Coloplast Corp | $71.15 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Pitruzzello listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.